Search
for
Sort by
Research 751–780 of 773
- Hair
- Gynostemma pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth-Inducing Properties In Vivo and In Vitro via the Wnt/β-Catenin Pathway in Dermal Papilla Cells
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- 83 Transcriptomic meta-analysis and deconvolution approaches unveil cellular dynamics in scarring and non-scarring primary lymphocytic alopecias
- Treatments for alopecia areata: a network meta-analysis
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- Review of efficacy of baricitinib in the treatment of alopecia areata
- Recent advances in the genetics of alopecia areata
- Referee report. For: Molecular mediators involved in skin healing: a narrative review [version 1; peer review: 1 approved with reservations]
- 1,314
- Hair Loss in an 11-year-old
- Androgenetic alopecia – Update 2022
- The Pathobiology of Skin Aging
- Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
- CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17
- Regenerative Medicine-Based Treatment for Vitiligo: An Overview
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics
- Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity
- Medical Dermatology
- Three Types of Alopecia in One Patient: A Case of Central Centrifugal Cicatricial Alopecia, Alopecia Areata, and Telogen Effluvium
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- Hair Disorders in Autoimmune Diseases
- Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Under Development JAK Inhibitors for Dermatologic Diseases
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- JAK inhibitors in dermatology: The promise of a new drug class
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata